# OnCo record nct06297226 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06297226/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06297226", "NCT06297226" ;
  schema:name "Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma"@en ;
  schema:alternateName "QUINTESSENTIAL"@en ;
  schema:description "A phase 2 trial of Arlocabtagene Autoleucel in multiple myeloma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06297226/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06297226> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-03-21" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:drugs <https://onco.cc/drugs/arlocabtagene-autoleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> .